[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500253":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Columbia University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Hypoparathyroidism Subjects",null,"Patients who have the disease hypoparathyroidism, who are being followed to monitor various aspects of the disease over time. No interventions.",{"label":13,"type":10,"description":14,"interventionNames":10},"Control Subjects","Healthy individuals to be followed to compare to hypoparathyroidism patients",[16],{"name":17,"affiliation":5,"role":18},"Mishaela Rubin, MD","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Noelle Texeira","CONTACT","212-305-2801","ngt2115@cumc.columbia.edu",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Aastha Mehta","212-342-0132","am5724@cumc.columbia.edu",[30],{"facility":31,"status":32,"city":33,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Columbia University Medical Center - Harkness Pavillion","RECRUITING","New York","10032","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-74.00597,40.71427,{"lat":41,"lon":40},[44,45],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":17,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":18,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Mishaela Rubin","Professor of Medicine","100500253","hypoparathyroidism-natural-history-study-100500253",false,"NCT05793853","Hypoparathyroidism Natural History Study","Advancing Product Development for Hypoparathyroidism: A Prospective Natural History Study of the Clinical Outcomes and Regulation of Disordered Mineral Metabolism","SHINE","Inclusion Criteria:\n\n* An understanding, ability and willingness to fully comply with study procedures and restrictions.\n* Ability to voluntarily provide written, signed and dated informed consent as applicable to participate in the study.\n* Male or female ≥18 years of age with HPT. All HPT sub-types are eligible, including surgical (HPT-S) and nonsurgical (HPT-NS) HPT: autoimmune, genetic (including but not limited to: DiGeorge syndrome, autoimmune polyendocrine syndrome type 1, hypoparathyroidism sensorineural deafness and renal disease syndrome, Kearns-Sayre syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes \\[MELAS\\] syndrome, mitochondrial trifunctional protein \\[MTP\\] deficiency syndrome, Kenny-Caffey syndrome, Sanjad-Sakati syndrome, autosomal dominant hypocalcemia), infiltrative (granulomatous), mineral deposition (copper, iron), metastatic, radiation and idiopathic HPT.\n* Diagnosis of HPT established based on historic hypocalcemia in the setting of inappropriately low serum PTH levels on two occasions.\n* All treatment regimens are permitted, including but not limited to conventional management with calcium (e.g. calcium citrate, calcium carbonate, etc), active vitamin D (calcitriol, alfacalcidol), parent vitamin D, magnesium, phosphate binders and thiazides. Use of PTH-like drugs are permitted.\n\nExclusion Criteria:\n\n* Functional HPT\n* Transient HPT\n* Pseudohypoparathyroidism\n* Pregnancy",true,"ALL","18 Years","100 Years",{"count":62,"type":63},106,"ESTIMATED","OBSERVATIONAL","This is a prospective three-year natural history study of adults with hypoparathyroidism. The goal is to monitor patients with hypoparathyroidism to define end-organ damage in the context of the disease.\n\nThe study objectives are to:\n\n1. Build a prospective cohort of patients to study HPT-associated end-organ damage.\n2. Determine end-organ physiologic consequences of HPT.\n3. Elucidate determinants of HPT-associated end-organ damage.\n\nFunding Source - FDA OOPD",[67],"Hypoparathyroidism","2025-12-08",{"date":70,"type":71},"2025-12-16","ACTUAL",{"date":73,"type":71},"2022-08-25",{"date":75,"type":63},"2026-12",{"name":5,"class":6},1]